Susan L. Kalled
Department of Inflammation
Biogen Inc.
Cambridge
Massachusetts 02142
USA
Name/email consistency: high
- BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders. Kalled, S.L., Ambrose, C., Hsu, Y.M. Expert Opin. Ther. Targets (2003)
- BAFF: a novel therapeutic target for autoimmunity. Kalled, S.L. Curr. Opin. Investig. Drugs (2002)
- Long-term anti-CD154 dosing in nephritic mice is required to maintain survival and inhibit mediators of renal fibrosis. Kalled, S.L., Cutler, A.H., Ferrant, J.L. Lupus (2001)
- Apoptosis and altered dendritic cell homeostasis in lupus nephritis are limited by anti-CD154 treatment. Kalled, S.L., Cutler, A.H., Burkly, L.C. J. Immunol. (2001)